Virtual Library
Start Your Search
X. Pan
Author of
-
+
P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.04-027 - The Expression of Fibroblast Activation Protein (FAP) in Human Lung Cancer Tissues and Its Clinical Significance (ID 2814)
09:30 - 17:00 | Author(s): X. Pan
- Abstract
Background:
To study the expression of fibroblast activation protein (FAP) in human lung cancer tissues and its clinical significance．
Methods:
Western-blot analysis was used to explore the expression of FAP in lung cancer tissues, paraneoplatic tissues (2cm beyond the cancer margin) and distal normal lung tissues(surgical resected specimens of lung tissue near the cut end) and also the lung cancer cell lines(A549, H1299, SPCA-1). Immunohistochemistry was performed to study the expression of FAP at protein level in tissues from 41 cases of lung cancer and 6 cases of benign pulmonary lesion．
Results:
Western blot analysis showed the expression of FAP was higher than in paraneoplatic tissues as well as normal lung tissues (P<0.05). It was also be positive in lung cancer cell lines (P<0.05). Immunohisto-chemistry showed that the positive rate of FAP staining was in fibroblast cells were 75.6%(31/41), the positive rate of FAP staining was in lung cancer cells were also 90.2%(37/41), whereas the expression in benign pulmonary lesion tissues was poor plus (1/6)．FAP expression was found to be significantly correlated with smoking status (x2=5.4085,P=0.02). However, there were no significant correlations between FAP and age, sex and TNM stage(P>0.05)．
Conclusion:
FAP could be over-expressed in lung cancer cells, which signifies that FAP also plays a role in the development of lung cancer and may serve as a potential biomarker in the treatment of lung cancer.
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-069 - Characteristics and PD-1/PD-L1 Expression of Periphera CD4+CD25+CD127low Treg Cells in Lung Cancer (ID 2741)
09:30 - 17:00 | Author(s): X. Pan
- Abstract
Background:
Both regulatory T cells (Tregs) and PD-1/PD-L1 pathway were critically involved in lung cancer. However, the association between them was not well investigated. Herein, we aimed to investigate the characteristics of PD-1 and PD-L1 expression on Tregs and association between them. Also, we analyzed the correlation between Tregs and clinical indicators of lung cancer and between PD-1,PD-L1 expressed by Treg and clinical indicators, thereby preliminary revealed the expression characteristics of PD-1,PD-L1 on Treg and its significant, and providing valuable indicators to clinical diagnosis.
Methods:
The phenotypic characteristics and PD-1 expression of CD4+CD25+CD127lowTreg were studied by flow cytometry. Twenty- two primarily lung cancer patients,ten patients with benign lung disease,twenty-five healthy volunteers were included.The datas were analyzed by SPSS 14.0 software.
Results:
1.The levels of CD4+CD25+CD127lowTreg in the peripheral blood of patients with lung cancer,with benign lung disease and healthy volunteers were (7.66土2.25%)、(5.73土1.43%)、(3.76土1.06%)respectively.The level of patients with lung cancer was significant higher than those of patients with benign lung disease and healthy volunteers.In the present study, PD-1 and PD-L1 expressions were detected in CD4+CD25+CD127lowTreg in both patients and health controls.The levels of PD-1 expression of CD4+CD25+CD127lowTreg were (46.01土11.33%)、(33.34土13.54%)respectively and the levels of PD-L1 expression of CD4+CD25+CD127low Treg were （73.39土11.64%）、（72.16土12.95%）respectively. Of note, higher level of PD-1 expression was found on tregs in patients with lung cancer. 2.The level of CD4+CD25+CD127lowTreg was not related to pathologic subtype and lymphatic metastasis, but clinical stage(stage Ⅲ6.29土1.18%，stage Ⅳ10.06土1.58%，P＜0.01). 3.The level of PD-1 expression of CD4+CD25+CD127lowTreg was not related to pathologic subtype,lymphatic metastasis ,but clinical stage(stage Ⅲ41.85土6.1%，stage Ⅳ56.57土12.52%，P＜0.05) .Moreover,the level of PD-L1 expression of CD4+CD25+CD127lowTreg was not associated with pathologic subtype and lymphatic metastasis, but clinical stage(stage Ⅲ48.51土18.17%，stage Ⅳ77.48土8.33%，P＜0.05).
Conclusion:
Costimulatory molecule receptor interacting with corresponding ligand mediate positive or negative costimulatory signal and regulate the proliferation of T cells, the production of cytokine, cell toxicity as well as cell apoptosis and existence, which control T cell activation. PD-1 (programmed cell death-1) belongs to the CD28 family and is expressed on activated T, B, and myeloid cells. PD-1 and its ligand PD-L1 deliver inhibitory signals that regulate the balance between effector T cell activation and immune-mediated tissue damage.The proliferation and immune inhibitory function of Treg is related to the costimulatory molecules expressed on its own surface.Our study showed that:1.The level of CD4+CD25+CD127lowTreg cells in the patients with lung cancer increased.The abnormal level of this negative immue cell may play an important role in the development,progression of lung cancer.2.Our study indicated that distinctive characteristics of PD-1 and PD-L1 expression on Tregs in lung cancer suggests associated with impaired adaptive immunity. The cross talk between Treg cells and PD-1/PD-L1 induced inhibition in lung cancer deserved further exploration for lung cancer associated immune pathogenesis.
